KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash: 2017-2025

Historic Change in Cash for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $154.7 million.

  • Amneal Pharmaceuticals' Change in Cash rose 438.71% to $154.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.1 million, marking a year-over-year increase of 1027.25%. This contributed to the annual value of $19.3 million for FY2024, which is 69.77% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Change in Cash is $154.7 million, which was up 912.80% from $15.3 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Cash peaked at $154.7 million during Q3 2025, and registered a low of -$172.7 million during Q2 2021.
  • Its 3-year average for Change in Cash is $18.5 million, with a median of $3.5 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 728.24% in 2023, then surged by 1,045.00% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Cash (MRQ) stood at -$53.9 million in 2021, then decreased by 12.59% to -$60.7 million in 2022, then surged by 105.77% to $3.5 million in 2023, then skyrocketed by 1,045.00% to $40.1 million in 2024, then soared by 286.11% to $154.7 million in 2025.
  • Its Change in Cash stands at $154.7 million for Q3 2025, versus $15.3 million for Q2 2025 and -$50.0 million for Q1 2025.